Demonstration of reperfusion after thrombolysis with technetium-99m isonitrile myocardial imaging.

Abstract

Technetium-99m isonitrile myocardial perfusion imaging was employed in a patient undergoing thrombolytic therapy with recombinant tissue plasminogen activator for acute anteroseptal myocardial infarction. Technetium-99m isonitrile does not demonstrate significant myocardial redistribution after intravenous injection. The imaging agent was administered in the emergency room, prior to the initiation of thrombolytic therapy. The initial area at risk for infarction was visualized on images obtained after the patient had been effectively treated. Imaging performed 5 days later, after repeat injection of [99mTc]isonitrile, showed a smaller myocardial perfusion defect indicating salvage of myocardium. Thus, this technique offers promise as a noninvasive means of assessing the area at risk, the success of reperfusion, and the presence of salvaged myocardium, early in the course of acute myocardial infarction.

• Authors: D S Kayden, J A Mattera, B L Zaret, F J Wackers
• Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 29 Issue 11 Pg. 1865-7 (Nov 1988) ISSN: 0161-5505 [Print] United States
• PMID: 2972815 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Fibrinolytic Agents
• Organometallic Compounds
• Recombinant Proteins
• Technetium
• Technetium Tc 99m Sestamibi
• Tissue Plasminogen Activator

Topics

• Fibrinolytic Agents (therapeutic use)
• Humans
• Male
• Middle Aged
• Myocardial Infarction (diagnostic imaging, drug therapy)
• Myocardial Reperfusion
• Organometallic Compounds
• Radionuclide Imaging
• Recombinant Proteins (therapeutic use)
• Technetium
• Technetium Tc 99m Sestamibi
• Tissue Plasminogen Activator (therapeutic use)